Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aurinia Pharmaceuticals Inc - Common Shares (NQ:AUPH)

15.54 -0.31 (-1.96%)
Streaming Delayed Price Updated: 9:59 AM EDT, Aug 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 96,894
Open 15.70
Bid (Size) 15.52 (400)
Ask (Size) 15.54 (200)
Prev. Close 15.85
Today's Range 15.52 - 15.95
52wk Range 10.34 - 19.25
Shares Outstanding 128,395,927
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire

Performance

YTD
+1.2%
+1.2%
1 Month
-1.5%
-1.5%
3 Month
-1.1%
-1.1%
6 Month
+7.0%
+7.0%
1 Year
+36.0%
+36.0%

More News

Read More
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Screens as Strong Candidate Based on Minervini Trend Template and High Growth Momentum Rating ↗
Via Chartmill
News headline image
Aurinia Pharmaceuticals' (AUPH) CEO Bought 815,000 Shares for $12.5 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) Screens Strong on Minervini Trend Template and High Growth Momentum ↗
Via Chartmill
AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH): A High-Growth Momentum and Technical Trend Case Study ↗
Via Chartmill
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Passes Key Growth Screener from "The Little Book That Makes You Rich" ↗
Via Chartmill
News headline image
LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Pharmaceuticals Completes Successful Tender Offer for Kezar Life Sciences
Via Newsfile
News headline image
Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals (NASDAQ:AUPH) Beats Q4 2025 Estimates and Provides 2026 Guidance ↗
Via Chartmill
News headline image
Earnings Scheduled For November 4, 2025 ↗
Via Benzinga
News headline image
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Announces Management Transition
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
AUPH Stock Gains On Aurinia Pharma’s Q4 Beat, But 2026 Guidance Misses Estimates ↗
Via Stocktwits
News headline image
Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake? ↗
Via The Motley Fool
News headline image
AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) Passes Louis Navellier's Strict Growth Stock Screen ↗
Via Chartmill
News headline image
Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
A Peek at Aurinia Pharmaceuticals's Future Earnings ↗
Via Benzinga
News headline image
FDA Drug Chief George Tidmarsh Resigns After Allegations Of Power Misuse ↗
Via Benzinga
News headline image
Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
FDA Turmoil Spills Over To Aurinia Pharma As Lawsuit Targets Ex-Drug Review Chief — Retail Traders Cry ‘Stock Manipulation’ ↗
Via Stocktwits
Topics Lawsuit
News headline image
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Shows Strong Growth Traits in Fundamental Analysis ↗
Via Chartmill

Frequently Asked Questions

Is Aurinia Pharmaceuticals Inc - Common Shares publicly traded?
Yes, Aurinia Pharmaceuticals Inc - Common Shares is publicly traded.
What exchange does Aurinia Pharmaceuticals Inc - Common Shares trade on?
Aurinia Pharmaceuticals Inc - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Aurinia Pharmaceuticals Inc - Common Shares?
The ticker symbol for Aurinia Pharmaceuticals Inc - Common Shares is AUPH on the Nasdaq Stock Market
What is the current price of Aurinia Pharmaceuticals Inc - Common Shares?
The current price of Aurinia Pharmaceuticals Inc - Common Shares is 15.54
When was Aurinia Pharmaceuticals Inc - Common Shares last traded?
The last trade of Aurinia Pharmaceuticals Inc - Common Shares was at 08/10/26 09:59 AM ET
What is the market capitalization of Aurinia Pharmaceuticals Inc - Common Shares?
The market capitalization of Aurinia Pharmaceuticals Inc - Common Shares is 2.00B
How many shares of Aurinia Pharmaceuticals Inc - Common Shares are outstanding?
Aurinia Pharmaceuticals Inc - Common Shares has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.